<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="abstract"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Pediatr Rheumatol Online J</journal-id><journal-title-group><journal-title>Pediatric Rheumatology Online Journal</journal-title></journal-title-group><issn pub-type="epub">1546-0096</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmc">3194540</article-id><article-id pub-id-type="publisher-id">1546-0096-9-S1-P184</article-id><article-id pub-id-type="doi">10.1186/1546-0096-9-S1-P184</article-id><article-categories><subj-group subj-group-type="heading"><subject>Poster Presentation</subject></subj-group></article-categories><title-group><article-title>Parental preferences for treatment: Preliminary report from a randomised comparison of treatment strategies in (early) juvenile idiopathic arthritis (BeSt for Kids trial)</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" id="A1"><name><surname>Muller</surname><given-names>PCE Hissink</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>p.hissinkmuller@lumc.nl</email></contrib><contrib contrib-type="author" id="A2"><name><surname>Brederije</surname><given-names>I</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A3"><name><surname>Brinkman DMC</surname><given-names>DMC</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A4"><name><surname>Allaart</surname><given-names>CF</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A5"><name><surname>van Suijlekom-Smit</surname><given-names>LWA</given-names></name><xref ref-type="aff" rid="I2">2</xref></contrib><contrib contrib-type="author" id="A6"><name><surname>van Rossum</surname><given-names>MAJ</given-names></name><xref ref-type="aff" rid="I3">3</xref></contrib><contrib contrib-type="author" id="A7"><name><surname>ten Cate</surname><given-names>R</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib></contrib-group><aff id="I1"><label>1</label>Department of Pediatric Rheumatology, LUMC, Leiden, The Netherlands</aff><aff id="I2"><label>2</label>Department of Pediatrics/Pediatric Rheumatology, Erasmus MC, Sophia Children&#x02019;s Hospital, Rotterdam, The Netherlands</aff><aff id="I3"><label>3</label>Department of Pediatric Rheumatology, Emma Children&#x02019;s Hospital, AMC, Amsterdam, The Netherlands</aff><pub-date pub-type="collection"><year>2011</year></pub-date><pub-date pub-type="epub"><day>14</day><month>9</month><year>2011</year></pub-date><volume>9</volume><issue>Suppl 1</issue><supplement><named-content content-type="supplement-title">Proceedings of 18th Pediatric Rheumatology European Society (PReS) Congress</named-content><named-content content-type="supplement-editor">Johannes Roth, Alberto Martini, Michael Hofer, Marco Gattorno, Hermann Girschick, Pierre Quartier, Carlos Rose, Rebecca ten Cate, Rolando Cimaz, Pavla Dolezalova, Sue Maillard and Carine Wouters</named-content></supplement><fpage>P184</fpage><lpage>P184</lpage><permissions><copyright-statement>Copyright &#x000a9;2011 Muller et al; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2011</copyright-year><copyright-holder>Muller et al; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><license-p>This is an open access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0">http://creativecommons.org/licenses/by/2.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xlink:href="http://www.ped-rheum.com/content/9/S1/P184"/><conference><conf-date>14-18 September 2011</conf-date><conf-name>18th Pediatric Rheumatology European Society (PReS) Congress</conf-name><conf-loc>Bruges, Belgium</conf-loc></conference></article-meta></front><body><sec><title>Aim</title><p>To prospectively determine treatment preferences among parents of patients with recent onset juvenile idiopathic arthritis participating in a randomized controlled trial comparing three therapeutic strategies.</p></sec><sec sec-type="methods"><title>Methods</title><p>A questionnaire is taken at the start in all parents of the participants of the BeSt for Kids trial, treated with either initial sequential monotherapy (group 1) with either methotrexate or sulfasalazine, initial combination therapy with methotrexate and tapered prednisone (group 2), or initial combination therapy with methotrexate and etanercept (group 3). ACRp50 is the primary goal, treatment adjustments are made every 3 months to aim at clinical remission on medication from 6 months and onwards. The questionnaire explores parental preferences or dislikes for the initial therapy.</p></sec><sec><title>Results</title><p>In total, parents of 31 out of 32 so far included patients (97%) completed the questionnaire. 38% of the parents expressed no preference and 53% of the parents expressed no aversion for a particular treatment group. 41% had hoped for assignment to group 3 and 6% had hoped against assignment to group 3. Primary aversion was highest in the second group with 25% due to disliking having to take prednisone.</p></sec><sec><title>Conclusions</title><p>This is the first prospective evaluation of parents&#x02019; preferences in newly diagnosed juvenile idiopathic arthritis patients participating in the BeSt for Kids trial. Within the limitations of the small amounts, patients clearly preferred initial combination therapy with etanercept and disliked taking prednisone. After actual exposure and follow up, this questionnaire will be repeated to see if preferences remain the same.</p></sec></body></article>